103 results on '"Dalakas, Marinos C."'
Search Results
2. Comment: Humoral and T-cell Immunities to SARS-CoV-2 Vaccines: Safety, Efficacy, and Challenges in Autoimmune Neurology
3. Peripheral Neuropathy Evaluations of Patients With Prolonged Long COVID
4. IgG4-Mediated Neurologic Autoimmunities: Understanding the Pathogenicity of IgG4, Ineffectiveness of IVIg, and Long-Lasting Benefits of Anti–B Cell Therapies
5. Cranial Neuropathies and COVID-19: Neurotropism and Autoimmunity
6. LGI1 encephalitis with squamous lung-cell carcinoma: Resolution after tumor resection
7. N2 year in review
8. Anti–SARS-CoV-2 antibodies in the CSF, blood-brain barrier dysfunction, and neurological outcome: Studies in 8 stuporous and comatose patients
9. Progress in the therapy of myasthenia gravis: getting closer to effective targeted immunotherapies
10. Cranial neuropathies and COVID-19: Neurotropism and autoimmunity
11. N2 year in review
12. Trial of canakinumab, an IL-1β receptor antagonist, in patients with inclusion body myositis
13. Obinutuzumab, a potent anti–B-cell agent, for rituximab-unresponsive IgM anti-MAG neuropathy
14. Antibodies to inositol 1,4,5-triphosphate receptor 1 in patients with cerebellar disease
15. Sialylation of IgG Fc domain impairs complement-dependent cytotoxicity
16. FOLLOW-UP NERVE CONDUCTION STUDIES IN CIDP AFTER TREATMENT WITH IGIV-C: COMPARISON OF PATIENTS WITH AND WITHOUT SUBSEQUENT RELAPSE
17. HMGB1 and RAGE in skeletal muscle inflammation: Implications for protein accumulation in inclusion body myositis
18. Inflammatory Muscle Diseases
19. Inflammatory Muscle Diseases
20. Autoimmune antigenic targets at the node of Ranvier in demyelinating disorders
21. Intravenous immunoglobulin in neurology—mode of action and clinical efficacy
22. Inclusion body myositis: from immunopathology and degenerative mechanisms to treatment perspectives
23. Immunology of stiff person syndrome and other GAD-associated neurological disorders
24. Progress and stiff challenges in understanding the role of GAD-antibodies in stiff-person syndrome
25. Fatigue-Related Gene Networks Identified in CD14+ Cells Isolated From HIV-Infected Patients—Part I: Research Findings
26. Fatigue-Related Gene Networks Identified in CD14+ Cells Isolated From HIV-Infected Patients—Part II: Statistical Analysis
27. Provision of an explanation for the inefficacy of immunotherapy in sporadic inclusion body myositis: Quantitative assessment of inflammation and β-amyloid in the muscle
28. Biologics and other novel approaches as new therapeutic options in myasthenia gravis: a view to the future
29. Clinical trials in CIDP and chronic autoimmune demyelinating polyneuropathies
30. Nitric oxide stress in sporadic inclusion body myositis muscle fibres: inhibition of inducible nitric oxide synthase prevents interleukin-1β-induced accumulation of β-amyloid and cell death
31. Advances in the diagnosis, pathogenesis and treatment of CIDP
32. Peripheral neuropathies in Sjögren syndrome: a new reappraisal
33. Potential biomarkers for monitoring therapeutic response in patients with CIDP
34. Inclusion-body myositis in the elderly: an update
35. A critical update on the immunopathogenesis of Stiff Person Syndrome
36. Electrophysiologic correlations with clinical outcomes in CIDP
37. Understanding the consequences of chronic inflammatory demyelinating polyradiculoneuropathy from impairments to activity and participation restrictions and reduced quality of life: the ICE study
38. Safety and Tolerability of Immune Globulin Intravenous in Chronic Inflammatory Demyelinating Polyradiculoneuropathy
39. Timing and Course of Clinical Response to Intravenous Immunoglobulin in Chronic Inflammatory Demyelinating Polyradiculoneuropathy
40. Inflammatory muscle diseases: a critical review on pathogenesis and therapies
41. Reply: Comment on alemtuzumab and inclusion body myositis
42. Immunotherapy of myositis: issues, concerns and future prospects
43. Pathogenesis and Treatment of Anti-MAG Neuropathy
44. Tragedy in a heartbeat: malfunctioning desmin causes skeletal and cardiac muscle disease
45. Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis
46. Inflammation interrelates to APP in sIBM: IL-1β induces accumulation of β-amyloid
47. ELECTROPHYSIOLOGY IN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY WITH IGIV
48. Stiff person syndrome: Advances in pathogenesis and therapeutic interventions
49. B cells as therapeutic targets in autoimmune neurological disorders
50. Interrelation of inflammation and APP in sIBM: IL-1β induces accumulation of β-amyloid in skeletal muscle
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.